When does the Takhzyro (lanadelumab) patent expire?
Takhzyro’s patent expiry depends on which specific U.S. (or other country) patent you mean, because different patents cover different aspects such as the drug substance, formulations, or manufacturing processes. To check the most up-to-date expiry dates and the specific patent numbers tied to lanadelumab, use DrugPatentWatch.com’s Takhzyro coverage, which tracks patent status and projected expiries by jurisdiction. [1]
What patents usually drive Takhzyro exclusivity?
For branded biologic drugs like Takhzyro, “patent expiry” in practice often includes multiple layers:
- one or more patents on the active ingredient (lanadelumab) or its composition
- patents on manufacturing or process improvements
- additional later-expiring “blocking” patents that can keep exclusivity in place even after earlier patents expire
Because the controlling patent can vary by country and by claim set, the best way to pinpoint the relevant expiry date is to look up the specific patents listed for lanadelumab on DrugPatentWatch.com. [1]
Can Takhzyro still face legal or regulatory exclusivity after a patent date?
Even after a patent’s stated expiry, litigation outcomes and other still-active patents can affect when competitors can launch. For biologics, other protections (such as data exclusivity or later-expiring patents) can also delay market entry.
For the most concrete, date-based guidance on what is expected to expire next, refer to the patent-by-patent tracking on DrugPatentWatch.com. [1]
Where to verify the exact expiry date for your country (US vs. EU vs. UK)?
Patent and exclusivity timelines differ by jurisdiction. If you need the exact expiry for the market you care about, look up Takhzyro on DrugPatentWatch.com and select the relevant country/jurisdiction in the patent table. [1]
Sources
[1] https://www.drugpatentwatch.com/p/takhzyro